Jean-Jacques Grob

TL;DR: The inhibition of two immune checkpoints, LAG-3 andPD-1, provided a greater benefit with regard to progression-free survival than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma.

TL;DR: Recommendations on CM diagnosis and treatment are made based on systematic literature reviews and the experts' experience, with a clear survival benefit and the presence of toxicity limit its use in practice.

TL;DR: In patients with advanced melanoma, ipilimumab 10 mg/kg resulted in significantly longer overall survival, but with increased treatment-related adverse events, while the treatment landscape for advanced melanomas has changed since this study was initiated.

TL;DR: The medical records of patients with a clinical suspicion of ICI-related cardiotoxicity were reviewed from the databases of 2 cardio-oncology units between March 2015 and April 2017 and found no specific follow-up had previously been established for patients receiving ICIs during the study period.

TL;DR: Efficacy outcomes seemed similar between patients who discontinued nivolumab plus ipilimumab treatment because of AEs during the induction phase and those who did not discontinue because of aEs, suggesting that many patients may continue to derive benefit from combination therapy even after discontinuation.